Pacific Biosciences of California, Inc. (PACB) key performance indicators and operating metrics (11 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Gross Margin (GAAP) | 35.00 percent | FY2026-Q1 |
| Consumables Revenue | 21.8M | FY2026-Q1 |
| Gross Margin (Non-GAAP) | 37.00 percent | FY2026-Q1 |
| Instrument Revenue | 9.7M | FY2026-Q1 |
| Revio Sequencing Systems Included in Instrument Revenue | 15.00 | FY2026-Q1 |
| Operating Expenses (Non-GAAP) | 49.9M | FY2026-Q1 |
| Service and Other Revenue | 5.6M | FY2026-Q1 |
| Annualized Consumable Pull-Through (Revio System) | 229K | FY2026-Q1 |
| Earnings per Share (Non-GAAP) | 0.12 USD_per_share | FY2026-Q1 |
| Vega Benchtar Platform Units Shipped | 27.00 | FY2026-Q1 |
| Gross Profit (Non-GAAP) | 17.8M | FY2025-Q4 |
Back to PACB overview · PACB earnings · PACB holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.